Xeris Pharmaceuticals, Inc. (XERS)
Stock Price:
$5.26 USD
-0.05 (-0.85%)
Updated Oct 27, 2020 12:43 PM EDT - Market open
Key Info
| Market Cap |
243.21M |
| Revenue (ttm) |
5.97M |
| Net Income (ttm) |
-119.20M |
| Shares Out |
46.28M |
| EPS (ttm) |
-3.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$5.26 |
| Previous Close |
$5.30 |
| Change ($) |
-0.05 |
| Change (%) |
-0.85% |
| Day's Open |
5.30 |
| Day's Range |
5.20 - 5.38 |
| Day's Volume |
267,625 |
| 52-Week Range |
1.42 - 9.69 |
More Stats
| Market Cap |
243.21M |
| Enterprise Value |
208.69M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.28M |
| Float |
44.67M |
| EPS (basic) |
-3.97 |
| EPS (diluted) |
-3.82 |
| FCF / Share |
-2.99 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
17.53M |
| Short Ratio |
4.98 |
| Short % of Float |
39.23% |
| Beta |
2.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
40.75 |
| PB Ratio |
10.44 |
| Revenue |
5.97M |
| Operating Income |
-113.34M |
| Net Income |
-119.20M |
| Free Cash Flow |
-113.64M |
| Net Cash |
34.52M |
| Net Cash / Share |
0.75 |
| Gross Margin |
18.67% |
| Operating Margin |
-1,898.84% |
| Profit Margin |
-1,997.00% |
| FCF Margin |
-1,903.90% |
| ROA |
-47.27% |
| ROE |
-240.39% |
| ROIC |
-89.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.00*
(109.32% upside)
Low
7.00
Current: $5.26
High
14.00
Target: 11.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 2.72 | 2.42 | 1.56 | 1.08 |
| Revenue Growth | 12.34% | 55.72% | 44.74% | - |
| Gross Profit | 1.12 | 2.42 | 1.55 | 1.07 |
| Operating Income | -122 | -59.34 | -26.63 | -13.23 |
| Net Income | -126 | -60.08 | -26.55 | -13.21 |
| Shares Outstanding | 26.11 | 12.05 | 2.03 | 1.84 |
| Earnings Per Share | -4.81 | -4.99 | -13.09 | -7.17 |
| Operating Cash Flow | -104 | -56.28 | -24.66 | -16.09 |
| Capital Expenditures | -1.11 | -1.51 | -0.70 | -0.04 |
| Free Cash Flow | -105 | -57.79 | -25.36 | -16.12 |
| Cash & Equivalents | 75.55 | 113 | 42.05 | 32.27 |
| Total Debt | 58.31 | 31.89 | - | - |
| Net Cash / Debt | 17.24 | 80.74 | 42.05 | 32.27 |
| Assets | 109 | 120 | 45.00 | 33.53 |
| Liabilities | 94.55 | 44.62 | 4.95 | 2.57 |
| Book Value | 14.44 | 75.41 | -57.83 | -31.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Xeris Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
188 |
| CEO |
Paul R. Edick |
Stock Information
| Ticker Symbol |
XERS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XERS |
| IPO Date |
June 21, 2018 |
Description
Xeris Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.